Nicholas La Thangue

Professor La Thangue has over 30 years of experience in biotech entrepreneurship, translational cancer science and drug development. He previously founded Prolifix focused on cell cycle therapeutics, where he acted as CSO and CEO until its merger with TopoTarget which led to a highly successful IPO. He also founded Oxford Cancer Biomarkers, which continues to develop a portfolio of marketed precision cancer medicine tests, where he held senior positions including CEO and CSO. Later on, Nick founded Celleron Therapeutics, a precision medicine company focusing on clinical stage oncology drugs. Argonaut Therapeutics, his most recently founded company, focuses on exploiting the PRMT5-E2F1 signalling pathway in cancer therapy. Nick is Professor of Cancer Biology at Oxford University. He is a Fellow of the Royal Society of Edinburgh, the Academy of Medical Sciences, the European Academy of Cancer Science, the Lister Institute and Professorial Fellow of Linacre College Oxford. He has over 200 publications and is an inventor on numerous patents.